Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
less,32726002,Relative attenuation ratios,"Relative attenuation ratios were less than 1, indicating a slower central versus peripheral attenuation, across the time points for all antipsychotic types and doses with only a few exceptions.",Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32726002/),,1,3875,DB00246,Ziprasidone
,25047407,peak plasma concentration (C max,"Systemic exposure to ziprasidone was similar following administration alone or after pretreatment with armodafinil, as assessed by mean peak plasma concentration (C max, 52.1 vs 50.4 ng/mL) and area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞, 544.6 vs 469.1 ng·h/mL).",Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047407/),[ng] / [ml],52.1,11110,DB00246,Ziprasidone
,25047407,peak plasma concentration (C max,"Systemic exposure to ziprasidone was similar following administration alone or after pretreatment with armodafinil, as assessed by mean peak plasma concentration (C max, 52.1 vs 50.4 ng/mL) and area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞, 544.6 vs 469.1 ng·h/mL).",Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047407/),[ng] / [ml],50.4,11111,DB00246,Ziprasidone
,25047407,area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞,"Systemic exposure to ziprasidone was similar following administration alone or after pretreatment with armodafinil, as assessed by mean peak plasma concentration (C max, 52.1 vs 50.4 ng/mL) and area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞, 544.6 vs 469.1 ng·h/mL).",Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047407/),[h·ng] / [ml],544.6,11112,DB00246,Ziprasidone
,25047407,area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞,"Systemic exposure to ziprasidone was similar following administration alone or after pretreatment with armodafinil, as assessed by mean peak plasma concentration (C max, 52.1 vs 50.4 ng/mL) and area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞, 544.6 vs 469.1 ng·h/mL).",Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047407/),[h·ng] / [ml],469.1,11113,DB00246,Ziprasidone
,21034370,time to peak plasma concentration,"time to peak plasma concentration occurs in 2 - 4 h but elimination half-life is 18 h for extensive CYP2D6 metabolizers and 33 h for poor CYP2D6 metabolizers, suggesting that once or twice daily dosing would be feasible.","Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034370/),h,2 - 4,26685,DB00246,Ziprasidone
,21034370,elimination half-life,"time to peak plasma concentration occurs in 2 - 4 h but elimination half-life is 18 h for extensive CYP2D6 metabolizers and 33 h for poor CYP2D6 metabolizers, suggesting that once or twice daily dosing would be feasible.","Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034370/),h,18,26686,DB00246,Ziprasidone
,21034370,elimination half-life,"time to peak plasma concentration occurs in 2 - 4 h but elimination half-life is 18 h for extensive CYP2D6 metabolizers and 33 h for poor CYP2D6 metabolizers, suggesting that once or twice daily dosing would be feasible.","Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21034370/),h,33,26687,DB00246,Ziprasidone
,10771450,"AUC(0,12 h)","The mean AUC(0,12 h) for ziprasidone was statistically significantly greater in the hepatically impaired subjects compared with the normal subjects (590 ng ml(-1) h vs. 467 ng ml(-1) h, P = 0. 042).",The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771450/),[h·ng] / [ml],590,35535,DB00246,Ziprasidone
,10771450,"AUC(0,12 h)","The mean AUC(0,12 h) for ziprasidone was statistically significantly greater in the hepatically impaired subjects compared with the normal subjects (590 ng ml(-1) h vs. 467 ng ml(-1) h, P = 0. 042).",The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771450/),[h·ng] / [ml],467,35536,DB00246,Ziprasidone
,10771458,"AUC(0,infinity)","Co-administration of ziprasidone with ketoconazole was associated with a modest increase in ziprasidone exposure; mean ziprasidone AUC(0,infinity) increased by 33%, from 899 ng ml(-1) h with placebo to 1199 ng ml(-1) h with ketoconazole.",The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771458/),[h·ng] / [ml],899,39121,DB00246,Ziprasidone
,10771458,"AUC(0,infinity)","Co-administration of ziprasidone with ketoconazole was associated with a modest increase in ziprasidone exposure; mean ziprasidone AUC(0,infinity) increased by 33%, from 899 ng ml(-1) h with placebo to 1199 ng ml(-1) h with ketoconazole.",The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771458/),[h·ng] / [ml],1199,39122,DB00246,Ziprasidone
,10771458,Cmax,"Mean Cmax increased by 34%, from 89 ng ml(-1) to 119 ng ml(-1), respectively.",The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771458/),[ng] / [ml],89,39123,DB00246,Ziprasidone
,10771458,Cmax,"Mean Cmax increased by 34%, from 89 ng ml(-1) to 119 ng ml(-1), respectively.",The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771458/),[ng] / [ml],119,39124,DB00246,Ziprasidone
<,16231965,time to reach peak serum concentration [tmax],"The pharmacokinetics of intramuscular ziprasidone include rapid attainment of therapeutic drug level (time to reach peak serum concentration [tmax]<or=60 minutes postdose), a mean terminal elimination half-life ranging from 2 to 5 hours, bioavailability of approximately 100%, exposure to drug that increases in a dose-related manner and little drug accumulation even after 3 days of repeated intramuscular administration.",Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231965/),min,60,41350,DB00246,Ziprasidone
,16231965,terminal elimination half-life,"The pharmacokinetics of intramuscular ziprasidone include rapid attainment of therapeutic drug level (time to reach peak serum concentration [tmax]<or=60 minutes postdose), a mean terminal elimination half-life ranging from 2 to 5 hours, bioavailability of approximately 100%, exposure to drug that increases in a dose-related manner and little drug accumulation even after 3 days of repeated intramuscular administration.",Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231965/),h,2 to 5,41351,DB00246,Ziprasidone
,16231965,bioavailability,"The pharmacokinetics of intramuscular ziprasidone include rapid attainment of therapeutic drug level (time to reach peak serum concentration [tmax]<or=60 minutes postdose), a mean terminal elimination half-life ranging from 2 to 5 hours, bioavailability of approximately 100%, exposure to drug that increases in a dose-related manner and little drug accumulation even after 3 days of repeated intramuscular administration.",Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16231965/),%,100,41352,DB00246,Ziprasidone
,9469675,AUC0-infinity,"Ziprasidone had a significant effect on area under the curve (AUC0-infinity), maximum serum concentration, and half-life (analysis of variance all p<0.05), with the mean AUC0-infinity being significantly greater (627.2 +/- 206.4 vs 371.0 +/- 126.5 ng x hr/ml, ANOVA with Bonferroni's criteria p<0.016) and half-life significantly shorter (4.7 +/- 0.8 vs 6.6 +/- 1.3 hrs, ANOVA with Bonferroni's criteria p<0.016) after treatment B compared with treatment A.",The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469675/),[h·ng] / [ml],627.2,55745,DB00246,Ziprasidone
,9469675,AUC0-infinity,"Ziprasidone had a significant effect on area under the curve (AUC0-infinity), maximum serum concentration, and half-life (analysis of variance all p<0.05), with the mean AUC0-infinity being significantly greater (627.2 +/- 206.4 vs 371.0 +/- 126.5 ng x hr/ml, ANOVA with Bonferroni's criteria p<0.016) and half-life significantly shorter (4.7 +/- 0.8 vs 6.6 +/- 1.3 hrs, ANOVA with Bonferroni's criteria p<0.016) after treatment B compared with treatment A.",The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469675/),[h·ng] / [ml],371.0,55746,DB00246,Ziprasidone
,9469675,half-life,"Ziprasidone had a significant effect on area under the curve (AUC0-infinity), maximum serum concentration, and half-life (analysis of variance all p<0.05), with the mean AUC0-infinity being significantly greater (627.2 +/- 206.4 vs 371.0 +/- 126.5 ng x hr/ml, ANOVA with Bonferroni's criteria p<0.016) and half-life significantly shorter (4.7 +/- 0.8 vs 6.6 +/- 1.3 hrs, ANOVA with Bonferroni's criteria p<0.016) after treatment B compared with treatment A.",The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469675/),h,4.7,55747,DB00246,Ziprasidone
,9469675,half-life,"Ziprasidone had a significant effect on area under the curve (AUC0-infinity), maximum serum concentration, and half-life (analysis of variance all p<0.05), with the mean AUC0-infinity being significantly greater (627.2 +/- 206.4 vs 371.0 +/- 126.5 ng x hr/ml, ANOVA with Bonferroni's criteria p<0.016) and half-life significantly shorter (4.7 +/- 0.8 vs 6.6 +/- 1.3 hrs, ANOVA with Bonferroni's criteria p<0.016) after treatment B compared with treatment A.",The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9469675/),h,6.6,55748,DB00246,Ziprasidone
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) was 272, 370, 250 and 297 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],272,62378,DB00246,Ziprasidone
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) was 272, 370, 250 and 297 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],370,62379,DB00246,Ziprasidone
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) was 272, 370, 250 and 297 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],250,62380,DB00246,Ziprasidone
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) was 272, 370, 250 and 297 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],297,62381,DB00246,Ziprasidone
,10771451,Cmax,"Corresponding mean Cmax values were 47, 61, 41 and 50 ng ml(-1) and corresponding mean tmax values were 5, 6, 5 and 5 h.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],47,62382,DB00246,Ziprasidone
,10771451,Cmax,"Corresponding mean Cmax values were 47, 61, 41 and 50 ng ml(-1) and corresponding mean tmax values were 5, 6, 5 and 5 h.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],61,62383,DB00246,Ziprasidone
,10771451,Cmax,"Corresponding mean Cmax values were 47, 61, 41 and 50 ng ml(-1) and corresponding mean tmax values were 5, 6, 5 and 5 h.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],41,62384,DB00246,Ziprasidone
,10771451,Cmax,"Corresponding mean Cmax values were 47, 61, 41 and 50 ng ml(-1) and corresponding mean tmax values were 5, 6, 5 and 5 h.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],50,62385,DB00246,Ziprasidone
,10771451,tmax,"Corresponding mean Cmax values were 47, 61, 41 and 50 ng ml(-1) and corresponding mean tmax values were 5, 6, 5 and 5 h.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),h,5,62386,DB00246,Ziprasidone
,10771451,tmax,"Corresponding mean Cmax values were 47, 61, 41 and 50 ng ml(-1) and corresponding mean tmax values were 5, 6, 5 and 5 h.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),h,6,62387,DB00246,Ziprasidone
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) were 446, 650, 389 and 427 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],446,62388,DB00246,Ziprasidone
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) were 446, 650, 389 and 427 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],650,62389,DB00246,Ziprasidone
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) were 446, 650, 389 and 427 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],389,62390,DB00246,Ziprasidone
,10771451,"AUC(0,12 h)","The mean AUC(0,12 h) were 446, 650, 389 and 427 ng ml(-1) h in groups 1, 2, 3 and 4, respectively.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[h·ng] / [ml],427,62391,DB00246,Ziprasidone
,10771451,Cmax,"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],68,62392,DB00246,Ziprasidone
,10771451,Cmax,"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],93,62393,DB00246,Ziprasidone
,10771451,Cmax,"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],54,62394,DB00246,Ziprasidone
,10771451,Cmax,"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),[ng] / [ml],70,62395,DB00246,Ziprasidone
,10771451,tmax,"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),h,4,62396,DB00246,Ziprasidone
,10771451,tmax,"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),h,5,62397,DB00246,Ziprasidone
,10771451,lambda(z),"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),1/[h],0.14,62398,DB00246,Ziprasidone
,10771451,lambda(z),"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),1/[h],0.11,62399,DB00246,Ziprasidone
,10771451,lambda(z),"Corresponding mean Cmax values were 68, 93, 54 and 70 ng ml(-1), corresponding mean tmax values were 4, 5, 4 and 5 h and corresponding mean lambda(z) were 0.14, 0.11, 0.14 and 0.17 h(-1).",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),1/[h],0.17,62400,DB00246,Ziprasidone
,10771451,"t(1/2),z","The mean percentage Fb was 99.84-99.88% across all groups and the mean t(1/2),z ranged from 4.2 to 6.4 h.",The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771451/),h,4.2 to 6.4,62401,DB00246,Ziprasidone
,10771448,Trough-to-peak ratios at steady state,Trough-to-peak ratios at steady state ranged from 2 to 5.,Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771448/),,2 to 5,73067,DB00246,Ziprasidone
,10771448,Accumulation ratios,"Accumulation ratios for the fixed-dose regimens were 1.49 and 1.48 at the 5 and 20 mg dose levels, respectively.",Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771448/),,1.49,73068,DB00246,Ziprasidone
,10771448,Accumulation ratios,"Accumulation ratios for the fixed-dose regimens were 1.49 and 1.48 at the 5 and 20 mg dose levels, respectively.",Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771448/),,1.48,73069,DB00246,Ziprasidone
,24491908,receptor occupancy levels,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,71.7,88871,DB00246,Ziprasidone
,24491908,receptor occupancy levels,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,64.3,88872,DB00246,Ziprasidone
,24491908,peak D2 receptor occupancy,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,75.4,88873,DB00246,Ziprasidone
,24491908,peak D2 receptor occupancy,"Estimated dopamine D2 receptor occupancy levels at trough were significantly higher in subjects who developed involuntary movements (N=23) than those who did not (N=195) (71.7±14.4% vs. 64.3±19.3%, p<0.05) while no significant difference was found in the estimated peak D2 receptor occupancy between them (75.4±8.7% vs. 72.1±9.9%, p=0.07).",Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24491908/),%,72.1,88874,DB00246,Ziprasidone
,22677485,flow rate,The mobile phase is acetonitrile-phosphate buffer (pH 3.6) 28:72% v/v at a flow rate of 1.0 mL/min.,High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677485/),[ml] / [min],1.0,110028,DB00246,Ziprasidone
,22677485,recoveries,"The mean recoveries of ZRS and IS are 79.32 ± 1.16 and 84.10 ± 3.2%, respectively.",High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677485/),%,79.32,110029,DB00246,Ziprasidone
,22677485,recoveries,"The mean recoveries of ZRS and IS are 79.32 ± 1.16 and 84.10 ± 3.2%, respectively.",High-performance liquid chromatographic assay for ziprasidone in plasma samples: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677485/),%,84.10,110030,DB00246,Ziprasidone
<,15901743,Tmax,Absorption of IM ziprasidone was rapid (Tmax < 1 hour).,"Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901743/),h,1,115327,DB00246,Ziprasidone
,15901743,elimination t(1/2),The mean IM elimination t(1/2) was short and approximately 2.5 hours.,"Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901743/),h,2.5,115328,DB00246,Ziprasidone
,15901743,bioavailability,The mean bioavailability for the 5-mg IM ziprasidone dose was approximately 100%.,"Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15901743/),%,100,115329,DB00246,Ziprasidone
,21838595,systemic clearance,"After intravenous injection, systemic clearance, steady-state volumes of distribution and half-life remained unaltered as a function of dose with values in the range 22.1-27.0 mL/min/kg, 2,380-2,850 mL/kg and 229-267 min, respectively.","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),[ml] / [kg·min],22,130368,DB00246,Ziprasidone
,21838595,steady-state volumes of distribution,"After intravenous injection, systemic clearance, steady-state volumes of distribution and half-life remained unaltered as a function of dose with values in the range 22.1-27.0 mL/min/kg, 2,380-2,850 mL/kg and 229-267 min, respectively.","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),[ml] / [kg],"2,380-2,850",130369,DB00246,Ziprasidone
,21838595,half-life,"After intravenous injection, systemic clearance, steady-state volumes of distribution and half-life remained unaltered as a function of dose with values in the range 22.1-27.0 mL/min/kg, 2,380-2,850 mL/kg and 229-267 min, respectively.","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),min,229-267,130370,DB00246,Ziprasidone
,21838595,absolute oral bioavailability,"Following oral administration, absolute oral bioavailability was not dose dependent with approximately 23%.","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),%,23,130371,DB00246,Ziprasidone
,21838595,recoveries,"The recoveries of lurasidone in urine and bile were 0.286% and 0.0606%, respectively.","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),%,0.286,130372,DB00246,Ziprasidone
,21838595,recoveries,"The recoveries of lurasidone in urine and bile were 0.286% and 0.0606%, respectively.","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),%,0.0606,130373,DB00246,Ziprasidone
,21838595,tissue-to-plasma ratios,"Lurasidone was primarily distributed to nine tissues (brain, liver, kidneys, heart, spleen, lungs, gut, muscle and adipose) and tissue-to-plasma ratios of lurasidone were ranged from 1.06 (brain) to 9.16 (adipose).","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),,1.06,130374,DB00246,Ziprasidone
,21838595,tissue-to-plasma ratios,"Lurasidone was primarily distributed to nine tissues (brain, liver, kidneys, heart, spleen, lungs, gut, muscle and adipose) and tissue-to-plasma ratios of lurasidone were ranged from 1.06 (brain) to 9.16 (adipose).","Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21838595/),,9.16,130375,DB00246,Ziprasidone
,10771456,renal clearance,Mean renal clearance of lithium decreased by 0.09 l h(-1) (5%) in the ziprasidone group and by 0.14 l h(-1) (9%) in the placebo group.,The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771456/),h(-·l,0,174992,DB00246,Ziprasidone
,10771456,renal clearance,Mean renal clearance of lithium decreased by 0.09 l h(-1) (5%) in the ziprasidone group and by 0.14 l h(-1) (9%) in the placebo group.,The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771456/),,0,174993,DB00246,Ziprasidone
,18950992,serum concentrations,"In patients who were at least much improved and defined as ""responders"" mean serum concentrations of ziprasidone were 80 ng/ml and 78 ng/ml in patients who did not reach this improvement score.",The use of ziprasidone in clinical practice: analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18950992/),[ng] / [ml],80,190877,DB00246,Ziprasidone
,18950992,serum concentrations,"In patients who were at least much improved and defined as ""responders"" mean serum concentrations of ziprasidone were 80 ng/ml and 78 ng/ml in patients who did not reach this improvement score.",The use of ziprasidone in clinical practice: analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18950992/),[ng] / [ml],78,190878,DB00246,Ziprasidone
,19726292,C(max),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),[ng] / [ml],170.7,201651,DB00246,Ziprasidone
,19726292,C(max),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),[ng] / [ml],174.4,201652,DB00246,Ziprasidone
,19726292,t(max),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),h,3.73,201653,DB00246,Ziprasidone
,19726292,t(max),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),h,3.69,201654,DB00246,Ziprasidone
,19726292,t((1/2)),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),h,5.57,201655,DB00246,Ziprasidone
,19726292,t((1/2)),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),h,5.61,201656,DB00246,Ziprasidone
,19726292,AUC(0-t),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),[h·ng] / [ml],1273,201657,DB00246,Ziprasidone
,19726292,AUC(0-t),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),[h·ng] / [ml],1296,201658,DB00246,Ziprasidone
,19726292,AUC(0-infinity),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),[h·ng] / [ml],1396,201659,DB00246,Ziprasidone
,19726292,AUC(0-infinity),"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),[h·ng] / [ml],1407,201660,DB00246,Ziprasidone
,19726292,relative bioavailability,"For the test and reference preparation, the pharmacokinetics parameter C(max) was 170.7-/+71.3 and 174.4-/+81.6 ng/ml, t(max) 3.73-/+1.87 and 3.69-/+1.84 h, t((1/2)) 5.57-/+1.62 and 5.61-/+1.73 h, AUC(0-t) 1273-/+252.3 and 1296-/+266.9 ng.h.ml(-1), and AUC(0-infinity)1396-/+276.9 and 1407-/+281.5 ng.h.ml(-1), respectively, with the relative bioavailability of (98.3-/+12.6)%.",[Pharmacokinetics and relative bioavailability of ziprasidone tablets in Chinese healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19726292/),%,98.3,201661,DB00246,Ziprasidone
,15121646,occup,"The mean 5-HT(2) receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively).",A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15121646/),%,76,224901,DB00246,Ziprasidone
,15121646,occup,"The mean 5-HT(2) receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively).",A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15121646/),%,56,224902,DB00246,Ziprasidone
,10771449,Cmax,Assessment of gender effects by analysis of variance revealed statistically significant differences in Cmax (85 vs.,Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),,85,248009,DB00246,Ziprasidone
,10771449,tmax,"69 ng ml(-1) and tmax (3.19 vs. 4.81 h) but no differences in AUC(0,12 h) or lambda(z).",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),h,3.19,248010,DB00246,Ziprasidone
,10771449,tmax,"69 ng ml(-1) and tmax (3.19 vs. 4.81 h) but no differences in AUC(0,12 h) or lambda(z).",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),h,4.81,248011,DB00246,Ziprasidone
,10771449,"AUC(0,12 h)","Assessment of age effects by analysis of variance revealed statistically significant differences in AUC(0,12 h) (560 vs.",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),,560,248012,DB00246,Ziprasidone
,10771449,Cmax,"465 ng ml(-1) h), Cmax (85 vs.",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),,85,248013,DB00246,Ziprasidone
,10771449,lambda(z),69 ng ml(-1) and lambda(z) (0.126 vs. 0.197 l h(-1) but no difference in tmax.,Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),[l] / [h],0.126,248014,DB00246,Ziprasidone
,10771449,lambda(z),69 ng ml(-1) and lambda(z) (0.126 vs. 0.197 l h(-1) but no difference in tmax.,Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),[l] / [h],0.197,248015,DB00246,Ziprasidone
,10771449,"t(1/2), z","The mean t(1/2), z in the young men, young women, elderly men and elderly women were 3.1, 4.1, 5.7 and 5.3 h, respectively.",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),h,3.1,248016,DB00246,Ziprasidone
,10771449,"t(1/2), z","The mean t(1/2), z in the young men, young women, elderly men and elderly women were 3.1, 4.1, 5.7 and 5.3 h, respectively.",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),h,4.1,248017,DB00246,Ziprasidone
,10771449,"t(1/2), z","The mean t(1/2), z in the young men, young women, elderly men and elderly women were 3.1, 4.1, 5.7 and 5.3 h, respectively.",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),h,5.7,248018,DB00246,Ziprasidone
,10771449,"t(1/2), z","The mean t(1/2), z in the young men, young women, elderly men and elderly women were 3.1, 4.1, 5.7 and 5.3 h, respectively.",Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771449/),h,5.3,248019,DB00246,Ziprasidone
,9224781,C(max),"The absorption of ziprasidone was rapid, and the C(max) for ziprasidone and metabolites occurred at 2 to 6 hr postdose.","Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224781/),h,2 to 6,253708,DB00246,Ziprasidone
,9224781,peak serum concentration,Mean peak serum concentration of unchanged drug was 45 ng/ml and a mean AUC(0-t) of 335.7 ng x hr/ml.,"Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224781/),[ng] / [ml],45,253709,DB00246,Ziprasidone
,9224781,AUC(0-t),Mean peak serum concentration of unchanged drug was 45 ng/ml and a mean AUC(0-t) of 335.7 ng x hr/ml.,"Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224781/),[h·ng] / [ml],335.7,253710,DB00246,Ziprasidone
,9224781,peak serum concentration,Mean peak serum concentration of total radioactivity (average of 3H and 14C) was 91 ng-eq/ml and a mean AUC(0-t) of 724.6 ng-eq x hr/ml.,"Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224781/),[ng-eq] / [ml],91,253711,DB00246,Ziprasidone
,9224781,AUC(0-t),Mean peak serum concentration of total radioactivity (average of 3H and 14C) was 91 ng-eq/ml and a mean AUC(0-t) of 724.6 ng-eq x hr/ml.,"Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9224781/),[h·ng-eq] / [ml],724.6,253712,DB00246,Ziprasidone
,10771454,tmax,The tmax for levonorgestrel was approximately 0.5 h longer.,Ziprasidone and the pharmacokinetics of a combined oral contraceptive. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771454/),h,0.5,267673,DB00246,Ziprasidone
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,66,268126,DB00246,Ziprasidone
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,39,268127,DB00246,Ziprasidone
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,2,268128,DB00246,Ziprasidone
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,62,268129,DB00246,Ziprasidone
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,35,268130,DB00246,Ziprasidone
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,-,268131,DB00246,Ziprasidone
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,6,268132,DB00246,Ziprasidone
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,68,268133,DB00246,Ziprasidone
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,47,268134,DB00246,Ziprasidone
,23417515,occupancies,"Eleven scans were available at each time point, and the mean occupancies at 5-, 13- and 23-h scans were 66, 39 and 2 % in the putamen; 62, 35 and -6 % in the caudate; and 68, 47 and 11 % in the ventral striatum, respectively.",Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),%,11,268135,DB00246,Ziprasidone
,23417515,occupancy half-life,The time-course of receptor occupancy across the regions indicated an occupancy half-life of 8.3 h.,Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417515/),h,8.3,268136,DB00246,Ziprasidone
